Yes, I believe we did. 🤩🤩🤩
With much of the clinical trial research world in catch up mode this past year, Leapcure was asked to help turn around a lot of research programs. Many clinical trial timelines needed rescuing to get on track and it was a tough year for maintaining stability with study staff through outbreaks. Fortunately, we started to see a significant shift in the way the way patient participation and engagement can work in clinical trials. We saw more patient voices and research coordinator voice be considered in our outreach strategies, at a pace we’ve never seen before.
From our most recent calculation Leapcure saved roughly 35 years of research across Rare Diseases, Infectious Diseases including COVID-19, Respiratory Disease, Oncology, Hematology and more just in 2021. We made this calculation when accounting for the combination of factors including accelerating timelines, cost savings against industry benchmarks, enrollments against industry benchmarks, and patient insights that helped clinical trials accelerate their results and helped lead to transformations in our understanding patient needs and clinician needs related to new treatments. We wouldn’t have been able to do this without sponsors buying into our model more – a lot was driven by our how well we collaborated through patient feedback to address clinical trial design gaps. By including each patient and researcher voice in program strategy, we’re able to be much nimbler at navigating how to provide better clinical trial support for patients.
To get there we had to continue to improve the way we run our business from creating new ways to engage advocacy communities, to the way our patient success team executed new patient learning goals, to evolving our insights model week in and week out. We doubled our team size for the second year straight (from organic growth) too. Most importantly, we’re learning how to listen better to each of the stakeholders involved in running clinical trials. It leaves us excited about what we’ll be able to learn next to speed up research in 2022.